New Research Shows Rapid Weight Gain After Stopping Weight-Loss Drugs
A recent study revealed that individuals who discontinue the use of the latest generation of weight-loss drugs gain weight back at a significantly faster rate compared to those who end diet and exercise programs. The study, conducted by British researchers and published in the BMJ journal, highlighted the challenges faced by individuals who rely on appetite-suppressing injectable drugs known as GLP-1 agonists for weight management.
The popularity of GLP-1 agonists has soared in recent years due to their efficacy in aiding weight loss of up to 15-20% of body weight. However, the study found that approximately half of the users discontinue the medication within a year, possibly due to side effects or high costs.
The study analyzed 37 trials and found that individuals regained an average of 0.4 kilograms per month after discontinuing the drugs. Participants who had lost nearly 15 kilograms while on semaglutide and tirzepatide regained 10 kilograms within a year of stopping the medication.
Lead author Sam West of Oxford University noted that weight regain was faster after medication cessation, regardless of the initial weight loss. This underscores the need for long-term strategies in obesity treatment, as these drugs serve as a starting point rather than a cure.
Long-Term Strategies in Obesity Management
The findings suggest that sustainable weight loss requires a combination of approaches, including diet, exercise, and therapies that address how the brain regulates energy balance. While GLP-1 agonists offer valuable support in weight management, they may need to be used continuously to maintain long-term results.
Dr. Garron Dodd, a metabolic neuroscience researcher, emphasized the importance of viewing these drugs as part of a comprehensive treatment plan rather than a standalone solution. Obesity is a chronic condition that requires ongoing management and lifestyle changes to achieve lasting results.
As further research unfolds, the role of weight-loss drugs in obesity treatment will likely be reevaluated to ensure that individuals receive effective and sustainable care for their weight management goals.
© Agence France-Presse
